An interventional study of Percutaneous coronary intervention in Coronary Artery Disease, sponsored by Samsung Medical Center. Active, not recruiting at 17 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2022, is one of 16 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 17th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,359 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 520 across the 21 interventional studies, 16,487 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
3 of the studies in Coronary Artery Disease by Samsung Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03169985Samsung Medical CenterRandomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque | 2027-01-28 |
| NCT04014803Samsung Medical CenterAspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion | 2027-06-30 |
| NCT05221931Samsung Medical CenterDrug-Coated Balloon in Patients With High Bleeding Risk | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
DCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial.
The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of de-novo coronary lesion in patients with high bleeding risk (HBR).
Second-generation DES is the standard of care for patients with coronary artery disease who are deemed eligible for percutaneous coronary intervention (PCI). Despite many advantages, DES inevitably accompany disadvantages such as the occurrence of late stent thrombosis and the need for maintaining dual antiplatelet (DAPT) for certain period due to permanent vascular implant, which lead to both increased ischemic and bleeding events.
As an alternative to DES, drug-coated balloon (DCB), a novel treatment strategy, which has benefit of having shorter DAPT maintenance duration due to the absence of metallic scaffolds and polymers, has been introduced. Based on meta-analysis based on many randomized clinical trials (RCT), its use has been established in in-stent restenosis of bare-metal stents (BMS) and DES. Furthermore, recently published RCT demonstrated efficacy and safety of DCB in de-novo coronary lesions in small vessels with reference vessel size\<3.0mm. However, studies exploring the feasibility of DCB in de-novo coronary artery stenosis beyond small vessels are limited. Furthermore, there is scarce data comparing DCB with DES in patients with de-novo coronary artery stenosis and high bleeding risk (HBR), a situation in which long-term maintenance of DAPT is a clinical dilemma. In previous BASKET-SMALL 2 trial, DCB showed noninferiority to DES in patients with de-novo coronary artery stenosis and small vessel disease. However, this trial was conducted in non-HBR patients, and the number of participated patients was insufficient. In another RCT, DEBUT trial exclusively enrolled patients with HBR and de-novo coronary artery stenosis. Although the DEBUT trial showed superiority of DCB angioplasty over implantation of BMS to treat de-novo coronary artery stenosis in patients with HBR, the results could not be applicable in contemporary practice because BMS has been no longer in clinical use. Recently, multiple RCTs have proved short-term DAPT (1-3 months) has comparable efficacy to longer term DAPT in HBR patients using latest second-generation DES.
On this background, the current trial aims to compare clinical outcomes between DCB and DES to treat de-novo coronary artery stenosis in patients with HBR receiving guideline-directed short-term DAPT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography. In DES group, latest second-generation DES will be used (Ultimaster Tansei) during the index procedure
Procedure: Percutaneous coronary intervention
Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography. In DCB group, Agent (Boston Scientific, USA), Prevail (Medtronic, USA), or SeQuent Please, SeQuent Please NEO (B-Braun, Germany) will be used during the index procedure.
Procedure: Percutaneous coronary intervention
1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])
Target vessel failure (TVF)
a composite of cardiovascular death, target-vessel myocardial infarction (MI), and clinically indicated target-vessel revascularization (TVR)
Time frame: 2 years from last patient enrollment
BARC type 2, 3 or 5 bleeding (Major secondary endpoint)
BARC type 2, 3 or 5 bleeding
Time frame: 2 years from last patient enrollment
Cardiovascular death
Cardiovascular death
Time frame: 2 years from last patient enrollment
All-cause death
All-cause death
Time frame: 2 years from last patient enrollment
Target-vessel MI
Target-vessel MI
Time frame: 2 years from last patient enrollment
Non-target vessel related MI
Non-target vessel related MI
Time frame: 2 years from last patient enrollment
Non-fatal MI
Non-fatal MI
Time frame: 2 years from last patient enrollment
Clinically indicated target-lesion revascularization (TLR)
Clinically indicated target-lesion revascularization (TLR)
Time frame: 2 years from last patient enrollment
Clinically indicated TVR
Clinically indicated TVR
Time frame: 2 years from last patient enrollment
Non-target vessel revascularization
Non-target vessel revascularization
Time frame: 2 years from last patient enrollment
Any revascularization
Any revascularization
Time frame: 2 years from last patient enrollment
Vessel or stent thrombosis
definite by Academic Research Consortium (ARC) definition
Time frame: 2 years from last patient enrollment
Cardiovascular death or target-vessel MI
Cardiovascular death or target-vessel MI
Time frame: 2 years from last patient enrollment
Target vessel failure without procedure-related MI
a composite of cardiovascular death, target-vessel myocardial infarction (MI) without procedure-related MI, and clinically indicated target-vessel revascularization (TVR)
Time frame: 2 years from last patient enrollment
Target lesion failure (TLF)
a composite of cardiovascular death, target-vessel MI, and clinically indicated TLR
Time frame: 2 years from last patient enrollment
Cardiovascular death, target-vessel MI, or vessel or stent thrombosis
Cardiovascular death, target-vessel MI, or vessel or stent thrombosis
Time frame: 2 years from last patient enrollment
All-cause death, non-fatal MI, or any revascularization
All-cause death, non-fatal MI, or any revascularization
Time frame: 2 years from last patient enrollment
Bleeding according to BARC definition
Bleeding according to BARC definition
Time frame: 2 years from last patient enrollment
Bleeding according to TIMI definition
Bleeding according to TIMI definition
Time frame: 2 years from last patient enrollment
Cerebrovascular accident (CVA)
Ischemic stroke, Hemorrhagic stroke, Transient ischemic attack (TIA)
Time frame: 2 years from last patient enrollment
Target vessel failure (TVF) at Extended Follow-up
a composite of cardiovascular death, target-vessel myocardial infarction (MI), and clinically indicated target-vessel revascularization (TVR) at Extended Follow-up
Time frame: 4 years from last patient enrollment
BARC type 2, 3 or 5 bleeding (Major secondary endpoint) at Extended Follow-up
BARC type 2, 3 or 5 bleeding at Extended Follow-up
Time frame: 4 years from last patient enrollment
Cardiovascular death at Extended Follow-up
Cardiovascular death at Extended Follow-up
Time frame: 4 years from last patient enrollment
All-cause death at Extended Follow-up
All-cause death at Extended Follow-up
Time frame: 4 years from last patient enrollment
Target-vessel MI at Extended Follow-up
Target-vessel MI at Extended Follow-up
Time frame: 4 years from last patient enrollment
Non-target vessel related MI at Extended Follow-up
Non-target vessel related MI at Extended Follow-up
Time frame: 4 years from last patient enrollment
Non-fatal MI at Extended Follow-up
Non-fatal MI at Extended Follow-up
Time frame: 4 years from last patient enrollment
Clinically indicated target-lesion revascularization (TLR) at Extended Follow-up
Clinically indicated target-lesion revascularization (TLR) at Extended Follow-up
Time frame: 4 years from last patient enrollment
Clinically indicated TVR at Extended Follow-up
Clinically indicated TVR at Extended Follow-up
Time frame: 4 years from last patient enrollment
Non-target vessel revascularization at Extended Follow-up
Non-target vessel revascularization at Extended Follow-up
Time frame: 4 years from last patient enrollment
Any revascularization at Extended Follow-up
Any revascularization at Extended Follow-up
Time frame: 4 years from last patient enrollment
Vessel or stent thrombosis at Extended Follow-up
definite ㅍessel or stent thrombosis at Extended Follow-up by Academic Research Consortium (ARC) definition
Time frame: 4 years from last patient enrollment
Target vessel failure without procedure-related MI at Extended Follow-up
a composite of cardiovascular death, target-vessel myocardial infarction (MI) without procedure-related MI, and clinically indicated target-vessel revascularization (TVR)
Time frame: 4 years from last patient enrollment
Cardiovascular death or target-vessel MI at Extended Follow-up
Cardiovascular death or target-vessel MI at Extended Follow-up
Time frame: 4 years from last patient enrollment
Target lesion failure (TLF) at Extended Follow-up
Target lesion failure (TLF) at Extended Follow-up
Time frame: 4 years from last patient enrollment
Cardiovascular death, target-vessel MI, or vessel or stent thrombosis at Extended Follow-up
Cardiovascular death, target-vessel MI, or vessel or stent thrombosis at Extended Follow-up
Time frame: 4 years from last patient enrollment
All-cause death, non-fatal MI, or any revascularization at Extended Follow-up
All-cause death, non-fatal MI, or any revascularization at Extended Follow-up
Time frame: 4 years from last patient enrollment
Bleeding according to BARC definition at Extended Follow-up
Bleeding according to BARC definition at Extended Follow-up
Time frame: 4 years from last patient enrollment
Bleeding according to TIMI definition at Extended Follow-up
Bleeding according to TIMI definition at Extended Follow-up
Time frame: 4 years from last patient enrollment
Cerebrovascular accident (CVA) at Extended Follow-up
Ischemic stroke, Hemorrhagic stroke, Transient ischemic attack (TIA)
Time frame: 4 years from last patient enrollment
Plan to share: Yes — After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Supporting information: Study protocol, Clinical study report
Time frame: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Access criteria: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Nov 2027, 64 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 64 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.